Four major receptor families enable cells to respond to chemical and physical signals from their proximal environment. The ligand-and voltage-gated ion channels, G-protein-coupled receptors, nuclear hormone receptors and receptor tyrosine kinases are all allosteric proteins that carry multiple, spatially distinct, yet conformationally linked ligand-binding sites. Recent studies point to common mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, pre-existing and functionally distinct conformational ensembles, intrinsically disordered regions, and the occurrence of allosteric modulatory sites. Importantly, synthetic allosteric modulators are being discovered for these receptors, providing an enriched, yet challenging, landscape for novel therapeutics.
| INTRODUCTION
One of the most important concepts in the biological sciences is the notion of the receptor, or "receptive substance," enunciated at the turn of the 20 th century by John Newport Langley in physiology and
Paul Ehrlich in immunology. It took, however, more than half a century to biochemically identify and discover the structure and dynamics of these receptor molecules, and to critically evaluate the role they play in the physiology of the organism, in particular the brain. 1 About 2% of the human genome encodes these receptors, which behave as the effective targets of nearly 60% of the medicines currently used in clinical practice.. These essential cybernetic sensors recognize chemical signals (such as neurotransmitters, hormones, odorants, and metabolites) and physical signals (including temperature, electric fields, and physical stress), and transduce them into a cellular response. They include four major superfamilies of proteins, namely: the ligand-gated (LGICs) and voltage-gated ion channels (VGICs), the G-protein-coupled receptors (GPCRs), the nuclear hormone receptors (NHRs), and the receptor tyrosine kinases (RTKs).
With the exception of the VGICs, which utilize physical activators such as voltage or temperature, the remaining canonical receptors utilize chemical messengers as the initiators of signal transduction.
Given the fact that receptors are the preeminent mediators of intercellular communication, they are also involved in numerous diseases spanning neurological disorders, cancers, cardiovascular, endocrinological, metabolic, and inflammatory diseases.
Signal transduction mediated by receptors involves, at the molecular level, a "communication over a distance" between the activating site and the locus of the biological response. An important conceptual advance was thus the proposal that the mechanism linking the activating and response sites is allosteric. Typically, an allosteric interaction 2,3 is defined as an indirect interaction between topographically distinct (non-overlapping) binding sites mediated by a discrete, reversible, conformational change in the protein structure referred to as the allosteric transition ( Figure 1 ). Moreover, many regulatory proteins function as discrete "cybernetic switches" exhibiting cooperative binding interactions with and between substrates and regulatory ligands. To account for this characteristic feature, it was proposed that allosteric proteins are organized into symmetrical oligomers that undergo, spontaneously, discrete cooperative changes of quaternary structure between a minimum of two states that pre-exist in equilibrium to ligand binding -summarized conceptually and in terms of thermodynamic linkages in Figure 1B (top, middle). The signal transduction mechanism would then operate through the selective stabilization of the particular state to which any ligand preferentially binds and is referred to as the "Monod-Wyman-Changeux" (MWC) model.
extended, the MWC model, emphasizing in particular "population shifts" of discrete conformations within an energy landscape formalism (see [10] [11] [12] [13] [14] ; Figure 1B , bottom).
The application of the MWC concept to membrane receptors, specifically neurotransmitter receptors, [15] [16] [17] considerably broadened its impact. 1 From a pharmacological viewpoint 18 ( Figure 1A ) receptors can thus be conceived as possessing three key binding loci, all of which are linked in an allosteric manner. These are: (1) the orthosteric site for endogenous or synthetic agonists, competitive antagonists, and physical signals; (2) the biologically active site, which includes the channel pore for LGICs/VGICs; the G-protein-binding site for GPCRs;
the tyrosine kinase domain of RTKs; the DNA response element for NHRs; and (3) more recently discovered allosteric modulatory sites, which are topographically distinct from the above mentioned sites. [18] [19] [20] [21] In this Review, we examine recent advances in understanding the mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, of pre-existing and functionally distinct conformational ensembles, a role for intrinsically disordered regions, and the occurrence of allosteric modulatory sites and their important pharmacological applications. proteins showing functionally important allosteric effects have been also highlighted, 11 especially in GPCRs. 22 Moreover, receptor oligomers are frequently made up of homologous subunits encoded by different genes, thus introducing pseudo-symmetry in their multiple assemblies.
| OLIGOMERIC VERSUS MONOMERIC ORGANIZATION OF RECEPTORS
The major subgroup of the LGICs ( Figure 2A ; 76 members in the human genome) first consists of the pentameric ligand gated ion channels (pLGICs), 23 which include the stimulatory nicotinic acetylcholine receptors (nAChRs) and serotonin (5HT 3 ) and the inhibitory glycine, glutamate, and GABA A receptors; second, the tetrameric ionotropic glutamate receptors (NMDA, AMPA, kainate); and third, the trimeric ATP-gated P2X receptors and acid-sensing channels. schematic summarizing the key conformationally linked sites common to all receptor superfamilies, namely, the "orthosteric site," which recognizes the endogenous agonist or physical activator, the "biologically active site," which propagates the initial stimulus imparted by the orthosteric ligand and one (or more) topographically distinct "allosteric sites" that modulate the interactive properties of the orthosteric and/or active sites via discrete conformational changes. (B) Schematic representations of the original MonodWyman-Changeux concerted model of allostery in terms of a minimum of two discrete, pre-existing states in equilibrium, "relaxed" (R) and "tense" (T), that can be differentially selected by various ligands. The three classes of molecules in the original conceptual model (top) were "activator" (A), "substrate" (S), and "inhibitor" (I) (from 4 ). The cubic model underneath re-casts the MWC model in terms of thermodynamic equilibrium linkages comprising unconditional isomerization (L) or dissociation constants (K A , K S ), and cooperativity factors (α, β, γ, δ), which yield conditional dissociation constants and are direct thermodynamic measures of the allosteric linkage governing the different transitions. 5, 6 The graph on the LGICs, which are composed of multiple subunits containing hydrophilic N-terminal regions and multiple hydrophobic M1-M4 TMD; the pore-forming M2 region is highlighted in red, and approximate location of the ECD and ICD is also indicated. (B) VGICs, which are comprised of a large, principal, α subunit and accessory β subunits. The α subunit is comprised of four domains, each consisting of six linked transmembrane segments (1) (2) (3) (4) (5) (6) , with the first four forming the voltage sensor, whereas segments 5 and 6 and the associated "P loop" contribute to the pore. (C) GPCRs, whose minimal functional unit is comprised of an extracellular N-terminal region, seven transmembrane-spanning domains (1-7) linked by three extracellular (e1-e3) and 3 intracellular (i1-i3) loops, and an intracellular C-terminal domain. Also shown in red is a heterotrimeric G protein. (D) RTKs have a highly modular structure comprised of subunits containing a large ECD, a TMD linked to a JMD, and the catalytically active intracellular TKD (red).
(E) NHRs also exhibit a modular structure containing an N-terminal activator function 1 (AF1) ligand independent-transactivation domain, a DBD, a variable hinge region and a C-terminal domain that contains both the ligand-binding domain (LBD) and the ligand-dependent transactivation domain (AF2), which co-binds co-regulators. In all instances (A-E), representative orthosteric binding domains are denoted in yellow.
symmetry, yielding a symmetry mismatch between the LBD and TMD layers and giving rise to two non-equivalent subunit pairs, A/C and B/D. 35 The NMDA receptor (NMDAR) 38, 39 44 revealed surprising similarities in the architecture and mechanisms utilized by these two distinct cation channels. 24 Both channels have six TM segments (two per subunit), short N and C termini, similar TM helical arrangements in the non-conducting states, and extracellular β sheets that "wrap" around 3-fold axes of symmetry. 24 In the agonist (ATP)-or gate-modifier (PcTX1)-bound structures, the putative orthosteric site is located at interfaces between adjacent subunits,~40 Å (ATP) or 50 Å (PcTX1) from the membrane bilayer. In short, all LGICs possess an oligomeric structure and show symmetry properties with ligand binding sites mostly at subunit interfaces.
VGICs ( Figure 2B ; 143 members in the human genome) comprise a large, channel-forming α subunit of~260 kDa, and one or two β subunits of 30-40 kDa. 45, 46 The structure of the α subunit of~2,000 amino acid residues from prokaryotic Na + VGIC shows four homologous domains with a 4-fold axis of pseudo-symmetry. 47 Each contains six TM segments (S1-S6) and an additional membrane re-entrant segment. Segments S1-S4 form the voltage-sensing module, whereas segments S5, S6, and the P loop between them form the pore.
In addition to extensively studied examples of VGICs such as those of the calcium, sodium, and potassium families, the transient receptor potential (TRP) channels are symmetrical homotetramers whose 3D structure resembles that of VGICs, wherein an ion permeation pathway is formed by S5 and S6, and the re-entrant pore loop region (S5-P-S6). This central pore is surrounded by four independently folded S1-S4 domains, which in the case of VGICs contain voltage sensors and undergo substantial movement during gating. In mammals, the TRPV1 subtype, 48 expressed by primary afferent nociceptors, shows large IC N-and C-terminal domains, which together account for 80% of the channel's mass and mediate extensive subunit interactions. Intersubunit interactions are facilitated by discrete substructures within the cytoplasmic domain, which may regulate channel assembly and/or facilitate concerted conformational changes after co-factor binding or agonist-evoked gating.
The orthosteric activator for VGICs is voltage itself, which modulates positive gating charges at intervals of three amino acid residues in the S4 TM segment, thus defined as the "orthosteric" site on these channels. 18, 49, 50 The largest receptor superfamily is the GPCRs (Figure 2C RTKs exist as monomers in the absence of ligand, but, in all instances, dimerization is part of the activation process. 69 To date, no full-length structure has been solved. At least four mechanisms, which vary by the extent to which the orthosteric ligand itself contributes to the dimerization interface. 68, 70 have been hypothesized for the dimerization process. These include direct cross-linking of two receptors by a bivalent orthosteric agonist, where the entire dimeric interface is provided by the ligand (e.g., nerve growth factor and its receptor TrkA ). Given this multiplicity of hypothetical mechanisms underlying RTK dimerization, both symmetric and asymmetric arrangements of the extracellular domains have been suggested, depending on the receptor and its agonist. 70, 75 Similar considerations apply to the TK domain. High-resolution structures have identified a putatively active conformation, 76 which requires a precise orientation of the "activation loop" and αC helix in the N-lobe of the TK to ensure coordination of ATP and catalysis of phosphotransfer. The key differences between RTKs with regards to the active site thus seem to arise from the transition of different inactive states to the final (common) active state. 68, 70, 77 The EGFR family represents a special case, utilizing a separate mechanism whereby two TK domains form an asymmetric dimer in which the C-lobe of one domain interacts with the N-lobe of the second domain to remove autoinhibitory constraints in the latter. 68, 70 Finally, the 48 human NHRs ( Figure 2E ) are ligand-regulated transcription factors with a conserved modular structure that comprises a disordered N-terminal domain, which contains a ligand-independent AF1 transactivation domain, a central DNA binding domain (DBD), a variable "hinge" region, and a C-terminal LBD that contains both the orthosteric site and a second AF2 transactivation domain, which carries the "coregulator" binding site. 78 The LBD of all NHRs consists of a three-layered helical sandwich with a hydrophobic pocket in which lipophilic ligands are captured and shielded from the solvent environment. 79 However, the ligand pockets of the NHRs exhibit a wide diversity of amino acid compositions such that they accommodate a broad variety of ligands within volumes that range from~30 to nearly 1,500 Å3. 80 It is well established that the majority of NHRs function as homoor hetero-dimers with only a subset of monomers, including many of the orphan NHRs. 78 There have been abundant high-resolution structures of various LBDs and DBDs in different states, but far fewer of complete multi-domain complexes of NHRs bound to their ligands, DNA, and any associated coregulators. The X-ray structures of the full eukaryotic nuclear PPARγ-RXRα (peroxisome proliferator-activated receptor-retinoid X receptor), the LXRβ/RXRα heterodimers and the hepatocyte nuclear factor 4α (HNF4α) homodimer, 81, 82 and the cryo-EM structure of the vitamin D receptor/, 83 each bound to DNA, show striking features in common, homologous to those of the muchstudied bacterial transcription factor, the lac repressor. 84 The DNA-bound lac repressor forms a symmetrical homodimer. 85 Despite manifest sequence differences in the eukaryotic heterodimers, the relative 3D arrangements of the proteins, the domain-domain interactions, and the interfaces with DNA resemble that of the lac repressor, with a pseudosymmetrical organization around an axis perpendicular to the DNA response element. However, the homodimeric HNF-4α-DNA structure adopts a surprisingly asymmetric organization, which is also evident when the overall domain architecture of this complex is overlaid on that of the heterodimeric PPARγ-RXRα-DNA. 82 In conclusion, a wealth of information from structural and functional studies points to oligomerization playing an important role in the function of all receptor families with the LGICs and VGICs sitting at one end of the spectrum where multimerization is essential and the GPCRs at the other. Comparison of the structures of the AMPAR by X-ray crystallography, 39 EPR spectroscopy and cryoEM 34 For the trimeric P2X and ASIC1a channels, the key steps in the allosteric transition are proposed to be an agonist-promoted outward movement of the TM domains lining the channel pore that is mediated by flexible β strands linking the (relatively rigid) amino terminal orthosteric ligand-binding domain to the channel. 24 In the case of the P2X4 receptor, the transition involves a relatively simple "irislike" rotation and pore expansion that maintains symmetry, whereas the movements within ASIC1a are qualitatively different because they are sensitive to pH state, retaining symmetry at low pH but becoming asymmetric at high pH. 44 In summary, these data are consistent with the general view that LGIC interfaces between subunits play a critical role in the allosteric transition. In the case of GPCRs, the best-studied, and conceptually most straightforward model is that of rhodopsin, which, despite proceeding through a series of very short-lived intermediate states, displays an almost "switch-like," two-state behavior in going from the fully inactive dark rhodopsin (which is pre-bound to the endogenous inverse agonist, 11-cis-retinal) to the fully all-trans-retinal bound active metarhodopsin II. 104 The characteristic features of the allosteric acti- and DBD, and through the computational identification of energetically preferred communication "pipeline" residues that have coevolved to link different surfaces across NHRs.
109-111
Similarly, with a lack of complete high-resolution structures of human RTKs in different states, the mechanisms governing allosteric transitions within these receptors remain an area of intense research.
Even though it is well acknowledged that the formation, or reorgani- LGICs, 31 GPCRs, 22 RTKs, 68 and, at a more preliminary stage, to NHRs 105,114-116 have now unambiguously confirmed this concept for receptors, with the extension of this notion to multi-state ensembles that are redistributed by the binding of ligand. 10, 11, 13, 115, 117 The data presently available in these diverse systems strongly support a conformational selection scheme rather than any induced-fit mechanism elicited by ligand binding.
| CONSTITUTIVE MUTATIONS AND RECEPTOR DISEASES
An important prediction of the MWC model is that the shift of the spontaneous equilibrium between active and inactive conformations by mutations, causing loss or gain of function, might be associated with disease states. 10 More than 1,000 activating and inactivating mutations in both LGICs and VGICs show that full channel openings may take place spontaneously and with high frequency in the absence of agonist. These mutations lead to diseases that include congenital myasthenia and autosomal dominant nocturnal epilepsy, hyperplexia, ataxia and cardiac arrhythmias, including the "long-QT syndrome". 118, 119 In the case of pLGICs these mutations are preferentially located either at the interface between subunits or within a given subunit at the interface between rigid domains of the receptor protein, 120 again highlighting the key role of oligomeric architecture on the function of allosteric proteins in both physiology and disease.
The overexpression of RTKs in the plasma membrane is well known to contribute to pathologies such as cancer due to inappropriate activation as a consequence of ligand independent dimerization. 70, 121 Similarly, naturally occurring mutations in RTKs increase catalytic activity and result in various clinical phenotypes. 77, 122 Mutations that disrupt key components of the allosteric transition in NHRs, such as ligand binding, dimerization and the ability to bind DNA, have been implicated in cancer, metabolic dysfunction, and sexual and developmental disorders. 123 Hundreds of gain-or loss-of function mutations have been identified in GPCRs. 124, 125 The mutations cause diseases such as retinitis pigmentosa, autosomal dominant hypocalcemia, hyperthryroidism, male-limited precocious puberty, familial short stature, and even some forms of obesity. 124, 125 Several of them change the basal activity of the receptor, which can be restored to the "resting activity" by the use of positive or negative allosteric modulators, depending on the context. 126 These observations clearly highlight the potential for pharmacotherapeutic approaches to correct for the inappropriate functionality of mutated (or overexpressed) receptors.
| THE PHENOMENON OF " BIASED AGONISM"
The concept of "biased agonism"-i.e., the ability of a ligand to stabilize distinct conformations of a given receptor such that only a subset of the possible signaling pathways mediated by that receptor are engaged, to the relative exclusion of other pathways-was first explicitly defined in studies of GPCRs. 127, 128 For example, Azzi et al. 129 demonstrated that previously classified "beta-blockers"
(i.e., clinically used competitive antagonists of the β 2 adrenergic receptor) could actually activate the MAP kinase pathway as agonists in a β-arrestin-dependent but G-protein-independent manner, thus highlighting the potential for the occurrence of multiple active conformations that differentially recognize transducers. This phenomenon was extended to various classes of GPCRs, 130 and biased agonism now represents a major paradigm in GPCR drug discovery. 128 The same phenomenon may exist in even earlier studies of NHRs, specifically in the context of compounds termed "selective NHR modulators," with tamoxifen being a prototypical example at the estrogen receptor. 78, 131 This drug demonstrates either proestrogenic or anti-estrogenic actions in a tissue-specific manner, thus being the first example of a "selective estrogen receptor modulator."
The simplest allosteric mechanism to account for biased agonism requires the existence of at least two-instead of one-active states, each possessing different agonist-binding specificities and signal transduction properties. 6, 132, 133 
| ALLOSTERIC MODULATORY SITES AND THEIR PHARMACOLOGY
Since the early discovery of benzodiazepines as GABA A receptor allosteric activators, it was shown that, most, if not all, cellular receptors possess, in addition to the orthosteric site, spatially distinct sites that modulate their allosteric transitions ( 18,19 ; Figure 5 ). Pharmacologically, allosteric ligands can be classed as "positive allosteric modulators" (PAMs), which enhance the effect of the orthosteric ligand, "negative allosteric modulators" (NAMs), which reduce the effect of the orthosteric ligand, and "neutral allosteric ligands" (NALs), which occupy the allosteric site, but do not modulate the effect of orthosteric ligand. A PAM may sometimes activate the receptor in the absence of agonist and is then referred to as an "allosteric agonist". 18 Combinations of these properties are also observed. 155 
| Allosteric sites on LGICs
Several allosteric sites have been identified in pLGICs, 19, 88 from ECD interfaces to the TMD and, potentially, the cytoplasmic face. For instance, Ca 2+ ions bind as PAMs in the ECD at the interface between subunits close to the TMD of α7 and α4β2 nAChRs. [156] [157] [158] [159] Ba 2+ binds as a NAM to a similar site on ELIC, 160 and GLIC shows a homologous pocket. 88 Given that most pLGICs are heterooligomers, the potential for non-agonist-binding ECD interfaces to harbor hitherto-unappreciated modulatory sites was predicted to be a likely general feature in such receptors, 161 and the best clinically validated examples of this are the benzodiazepines, which indeed bind as
PAMs to a non-agonist ECD interface in the GABA A receptor. 162, 163 In contrast, the anthelminthic PAM, ivermectin, binds within the α7nAChR TMD, 164 as do synthetic PAMs, such as PNU-120596 and LY2087101. 165, 166 In the GLIC structure, the general anesthetics (GAs), isoflurane and propofol, bind in the upper half of the TMD that is accessible from the lipid bilayer. 167 An ivermectin site ( Figure 4 ) is also seen in the GluCl structure 27 in the periphery of the TMD at subunit interfaces. The intersubunit TMD cavity is conserved in human glycine and GABA A receptors, involving residues that influence ethanol and anesthetic action. [168] [169] [170] Computational analyses of the cryo-EM structure of the Torpedo nAChR 171 More recently, allosteric NMDAR modulators have been identified within the vicinity of the LBD, typified by compounds such as TCN-201, DQP-1105, UPB512, and QNZ46. 174 Less is known about the potential for allosteric sites in the TMD or intracellular domains of the NMDAR, although it has been suggested that the small molecule, CIQ, and the endogenous neurosteroid, pregenolone sulphate, are PAMs via the TMD. 174 In contrast to the NMDAR, the LBD of the AMPAR appears to be the major site for allosteric modulators, including the ions, Cl − and Na + , as well as synthetic PAMs that include aniracetam, cyclothiazide, and biaryl propylsulfonamides. 176 Last but not least, recent structural and dynamic studies with
LGICs demonstrate that, in agreement with their differential effects on the allosteric equilibrium, the structure(s) of allosteric modulatory site(s) differ between resting and active states. For example, a close comparison of the X-ray structures of active and resting conformations in GLIC 88 and MD simulations with GluCl 90 reveal that, during activation in GLIC, a tertiary change significantly reshapes the subunit interface and the binding pocket homolog of the PAM Ca 2+ site and that, in GluCl, removal of ivermectin from its TM site shrinks substantially by receptor twisting. 88 This observation has important consequences for the design of allosteric modulatory drugs.
| Allosteric sites on VGICs
There is a rich repertoire of neurotoxins and drugs that bind allosterically in VGICs. For sodium channels (NaV), there are at least six dis- zepines (e.g., diltiazem), which act within the pore, or dihydropyridines (e.g., amlodipine), which act as gating modifiers (Table 1 ). There are also neurotoxins, such as ω-conotoxin GVIA and ω-agatoxin IVA, which act as pore blockers or gating modifiers, respectively. 
| Allosteric sites on GPCRs
Most GPCRs possess at least one, if not more, allosteric modulatory sites. 184, 185 Furthermore, two GPCR allosteric modulators, maraviroc (CCR5 NAM) and cinacalcet (calcium-sensing receptor PAM), are on the market. 18 The majority of synthetic GPCR allosteric modulators identified to date bind within the TMD region, but the location within the TMD cavity can vary dramatically depending on the receptor class. This variability is due to the high degree of both sequence and tertiary structure divergence in the orthosteric domain for these receptors. 185, 186 An important finding contributing to understanding the structural basis of GPCR allosteric modulatory sites was the solution of two crystal structures of an active M 2 muscarinic receptor, concomitantly bound to an orthosteric agonist and a G protein mimetic nanobody and either the absence or presence of the small molecule PAM, LY2119620 (Figure 4  187 ). These two structures clearly delineated the allosteric transition between active and inactive states but also revealed very little difference in the allosteric pocket in the absence or presence of the PAM. 187 This comparison suggests that the modulatory site is "pre-formed" upon transition to the active state, a mechanism consistent with a MWC scheme whereby the effect of the PAM is to preferentially stabilize this state. 188 It remains to be seen how generalizable the above mechanism is. Interestingly, mutagenesis studies have also identified putative intracellular allosteric sites for synthetic modulators of some chemokine receptors, and novel lipidated peptides ("pepducins") have been designed to specifically modulate the intracellular surfaces of different GPCRs. 185 Finally, it is worth highlighting that there remain numerous pharmacological examples of GPCRs that display cooperativity in their modes of interaction with both cognate and synthetic ligands, suggesting that the potential for interactions across GPCR oligomeric arrays is also possible. Other allosteric RTK antibodies have been discovered, such as XMetA and XMetS, which bind to the ECD of the insulin RTK and activate the receptor or act as an insulin-sensitizing PAM. 192, 193 Allosteric ECD interactions have also been identified at RTKs mediated by peptidomimetics. 189 Most recently, the first ECD small-molecule RTK inhibitor was identified ( Figure 5 ). SSR128129E interacts with the D2D3 domain of multiple FGFRs 194 to inhibit hormone signaling in a clearly allosteric manner. 195 Finally, a less-characterized RTK target is the juxtamembrane/TM region. However, recent work from Jang et al. 196 identified an allosteric agonist, gambogic amide, which selectively binds to this region of the TrkA RTK.
| Allosteric sites on NHRs
There is no current consensus on the importance of targeting allosteric modulator sites on NHRs. 197 Furthermore, virtually all clinically relevant targeting of NHRs to date has been via orthosteric drugs. 78 Nonetheless, "alternate" pockets distinct from the orthosteric site have been identified in some. 78, 197, 198 The extent to which these sites unambiguously modulate orthosteric ligands remains largely undetermined, however, and we thus refer to them as "putative allosteric sites."
There are at least five potential alternate binding surfaces on NHRs ( Figure 5 ). The best-studied is the AF2 coregulator site. [198] [199] [200] An exemplar AF2-targeting molecule, HPPE, binds covalently at the interface between the LBD-AF2 binding interface. 201 A second LBD surface identified adjacent to AF2 on the androgen receptor, termed "binding function 3", 202 recognizes molecules such as 3,3,5-triiodothyroacetic acid and may be found on other NHRs. 203 Hughes et al. 197 identified a third LBD pocket in the PPARγ receptor that binds synthetic molecules concomitantly to the orthosteric site. Other molecules have been described that interact with nuclear response elements and with zinc fingers in the DBD, such as the estrogenreceptor-targeting compound DIBA. 198 Finally, at least one small molecule that blocks transactivation of the androgen receptor, EPI-001, interacts within the intrinsically disordered AF1 region. Finally, it is worth noting that the allosteric concept, as applied to regulatory proteins and now receptors, can also be extended to even larger protein assemblies, 10, 16 creating important functional links between the molecular and cellular levels through large-scale allosteric transitions. This represents fertile ground for future studies of "supramolecular" protein assemblies.
| Toward a new pharmacology
Until relatively recently, drugs were classically designed following the concept of direct competitive interactions between ligands for a common "rigid" site. 210, 211 The discovery of the intrinsic flexibility of allosteric proteins, and of allosteric modulatory sites on all classes of receptor ( Figure 5 ), supersedes the notion of "rigid site" pharmacology and opens the field to the design of new categories of "conformation-specific" drugs that interact à distance with topographically distinct active sites. This concept applies to both orthosteric ligands and allosteric modulators because the binding pockets for either class concomitantly change between states during the allosteric transition that underlies receptor signal transduction. 31, 88, 212 However, a specific advantage of targeting allosteric modulator sites over orthosteric sites is that the former can exhibit a higher degree of sequence diversity between receptor subtypes, thus providing a degree of selectivity in receptor targeting that is simply unattainable with many orthosteric agonists/antagonists. 20, 185 It should also be noted that allosteric targeting need not be achieved solely through the design of synthetic small molecules, but also can also be reached via conformationally specific allosteric antibodies, which represents an important field of future research. There are already clear examples of monoclonal antibodies that allosterically target ion channels, 213 GPCRs, 214 and RTKs, 189 as well as cytokine and integrin receptors. 215, 216 However, because allosteric modulators can display a diverse spectrum of effects, usually in a "context-dependent" manner, 18 traditional biochemical approaches are suboptimal for studying such molecules, and functional screening methods are still being developed to maximize the detection of allosteric effects. 217 Furthermore, as discussed above, most receptors are oligomers, and thus their subunit assembly and stoichiometry can have a dramatic effect on screening for allosteric modulator activity. 212 Finally, it is important to note the potential for endogenous allosteric substances that may play important roles in both health and disease. 218 Such drug discovery challenges can be better addressed as more structural data on allosteric sites and transitions become available.
Interestingly, at the time of writing, a curated online "allosteric database" 219 classifies nearly 72,000 substances as allosteric modulators (http://mdl.shsmu.edu.cn/ASD/), which attests to the ongoing growth and interest of the phenomenon and even allows one to envisage the concept of an "allosterome" as a valuable resource for new chemical, cellular, molecular and structural biology breakthroughs. As highlighted by the selected examples in Table 1 , there is already clear evidence for success in allosteric pharmacology for receptors and enzymes.
In conclusion, it is now clear that substantial opportunities exist for allosteric targeting of all receptor families. This is a critical pursuit because allosteric medicines have the potential to display conformation-and site-based selectivity, pathophysiologically relevant "context-sensitivity," and greater mechanism-based on-target Data collated from the Thomson Reuters Cortellis Database, using the search term "allosteric," followed by manual inspection and literature-based validation of mechanism of each entry by the authors. The only exceptions were trastuzumab and pertuzumab, the mechanism of which was taken from Cho et al. 182 and Franklin et al. 183 "PAM" denotes "postitive allosteric modulator" and "NAM" denotes "negative allosteric modulator." safety than traditional orthosteric activators or blockers. Despite being recognized over 50 years ago, the concept of allosteric interaction, as illustrated in this Review, continues to blossom with its extension to all receptors and is yielding new and fertile avenues for research across the life sciences.
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